[go: up one dir, main page]

GB0426481D0 - Composition - Google Patents

Composition

Info

Publication number
GB0426481D0
GB0426481D0 GBGB0426481.8A GB0426481A GB0426481D0 GB 0426481 D0 GB0426481 D0 GB 0426481D0 GB 0426481 A GB0426481 A GB 0426481A GB 0426481 D0 GB0426481 D0 GB 0426481D0
Authority
GB
United Kingdom
Prior art keywords
composition
antigen
immune
allergen
receptor ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0426481.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccine Tech Ltd
Original Assignee
Vaccine Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccine Tech Ltd filed Critical Vaccine Tech Ltd
Priority to GBGB0426481.8A priority Critical patent/GB0426481D0/en
Publication of GB0426481D0 publication Critical patent/GB0426481D0/en
Priority to EP05813465A priority patent/EP1827488B1/en
Priority to US11/720,284 priority patent/US8765721B2/en
Priority to MX2007006518A priority patent/MX2007006518A/en
Priority to PCT/GB2005/004656 priority patent/WO2006059142A1/en
Priority to AT05813465T priority patent/ATE513559T1/en
Priority to NZ554974A priority patent/NZ554974A/en
Priority to CA002587247A priority patent/CA2587247A1/en
Priority to JP2007543927A priority patent/JP2008521871A/en
Priority to AU2005311034A priority patent/AU2005311034A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)

Abstract

Provided is a composition comprising a phosphatidyl serine receptor ligand for use in immune therapy. The composition may include an antigen or allergen together with the phosphatidyl serine receptor ligand. The compositions may be used for any type of immune therapy, such as immune modulation to an environmental antigen or allergen, down regulation of immune hypersensitivity reactions, and stimulation of antigen or allergen specific IgA and/or IgG4.
GBGB0426481.8A 2004-12-02 2004-12-02 Composition Ceased GB0426481D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0426481.8A GB0426481D0 (en) 2004-12-02 2004-12-02 Composition
AU2005311034A AU2005311034A1 (en) 2004-12-02 2005-12-02 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof
PCT/GB2005/004656 WO2006059142A1 (en) 2004-12-02 2005-12-02 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof
US11/720,284 US8765721B2 (en) 2004-12-02 2005-12-02 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof
MX2007006518A MX2007006518A (en) 2004-12-02 2005-12-02 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof.
EP05813465A EP1827488B1 (en) 2004-12-02 2005-12-02 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof
AT05813465T ATE513559T1 (en) 2004-12-02 2005-12-02 COMPOSITION CONTAINING PHOSPHATIDYLSERINE AND AN ANTIGEN OR ALLERGEN AND THEIR USE
NZ554974A NZ554974A (en) 2004-12-02 2005-12-02 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof
CA002587247A CA2587247A1 (en) 2004-12-02 2005-12-02 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof
JP2007543927A JP2008521871A (en) 2004-12-02 2005-12-02 Composition comprising phosphatidylserine and an antigen or allergen, and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0426481.8A GB0426481D0 (en) 2004-12-02 2004-12-02 Composition

Publications (1)

Publication Number Publication Date
GB0426481D0 true GB0426481D0 (en) 2005-01-05

Family

ID=34043954

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0426481.8A Ceased GB0426481D0 (en) 2004-12-02 2004-12-02 Composition

Country Status (10)

Country Link
US (1) US8765721B2 (en)
EP (1) EP1827488B1 (en)
JP (1) JP2008521871A (en)
AT (1) ATE513559T1 (en)
AU (1) AU2005311034A1 (en)
CA (1) CA2587247A1 (en)
GB (1) GB0426481D0 (en)
MX (1) MX2007006518A (en)
NZ (1) NZ554974A (en)
WO (1) WO2006059142A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3056214T (en) * 2008-06-27 2019-06-10 Zoetis Services Llc Novel adjuvant compositions
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
EP3251662A1 (en) * 2016-06-07 2017-12-06 Tolerogenics S.à.r.l. Matrix-embedded tolerance-promotion adjuvants for subcutaneous immunotherapy
US11123324B2 (en) 2016-08-18 2021-09-21 Noster Inc. Immunomodulator
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107536B2 (en) 1987-06-11 1995-11-15 鐘淵化学工業株式会社 Highly sensitive immunoassay using liposome
NZ230424A (en) 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
KR950700083A (en) 1992-03-03 1995-01-16 스즈키 다다시 ORAL VACCINE
JPH05339169A (en) * 1992-03-03 1993-12-21 Dai Ichi Seiyaku Co Ltd Oral vaccine
JPH0912480A (en) 1995-06-30 1997-01-14 Nippon Oil & Fats Co Ltd Antigen-bound liposome vaccine
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6300308B1 (en) 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments

Also Published As

Publication number Publication date
US20080107684A1 (en) 2008-05-08
ATE513559T1 (en) 2011-07-15
AU2005311034A1 (en) 2006-06-08
JP2008521871A (en) 2008-06-26
CA2587247A1 (en) 2006-06-08
US8765721B2 (en) 2014-07-01
EP1827488B1 (en) 2011-06-22
EP1827488A1 (en) 2007-09-05
MX2007006518A (en) 2007-11-15
WO2006059142A1 (en) 2006-06-08
NZ554974A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
HRP20181459T1 (en) Humanized anti-beta7 antagonists and uses thererfor
EP1871341B8 (en) Charged lipoprotein complexes and their uses
IL245462A0 (en) Humanized anti-cmet antagonists
MX2009008918A (en) Activation of human antigen-presenting cells through clec-6.
EP1832272B8 (en) Modified powder and cosmetic composition using same
MA28985B1 (en) LOXAPINE ANALOGUES AND METHODS OF USE
WO2006034039A3 (en) Substituted morphinans and methods of their use
WO2006052534A3 (en) Expansion of nk cells and therapeutic uses thereof
ZA200700616B (en) Modified pyrimidine glucocorticoid receptor modulatore
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
PL1800693T3 (en) Adjuvant therapy with the use of anti-glypican 3 antibody
GB0426481D0 (en) Composition
TW200634085A (en) Elastomer composition and molded body
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
WO2006103568A3 (en) NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF
WO2005040339A3 (en) Aptamers to human epidermal growth factor receptor-3
WO2005086938A3 (en) Artificial mutation controls for diagnostic testing
AU2003255337A1 (en) Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
GB0423008D0 (en) Organic compounds
WO2007073567A3 (en) Compositions and methods of modulating the immune response
AU2003294499A1 (en) Rhebs as modifiers of the rb pathway and methods of use
AU302366S (en) Safety change belt
IL160576A0 (en) PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF INTRACELLULAR Ca 2+ AND METHODS FOR THE USE THEREOF
AU301377S (en) Mixing bowl

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)